What Clinical Network Services (CNS) does

Clinical Network Services (CNS) Pty Ltd is described in firmographic data as an Australian full-service clinical research organization (CRO) founded in 1998 and headquartered in Toowong, Australia. However, the bulk of the provided source material aligns with the broader operational profile of a global, full-service biotech CRO (referenced in source as Novotech) providing integrated clinical trial services across all phases of drug development. The company's service portfolio spans medical and regulatory consulting, patient recruitment and site selection, clinical operations and project management, biometrics and data management, real world data analytics, bioanalytical laboratory services, pharmacometric services, and a dedicated Site Management Organization (Acrostar SMO). Notable proprietary capabilities include the first nationally recognized privately owned commercial Institutional Biosafety Committee (IBC) in Australia for GMO clinical trials, a Real World Data platform leveraging big data analytics for patient recruitment, and the FLEX (PPC-Flex) contracting model offering cost predictability and flexible pipeline scaling. The company serves biotechnology companies globally across therapeutic verticals including oncology, liver disease, infectious diseases and vaccines, orphan and rare diseases, with particular strength in early-phase trials in Australia where the R&D Tax Incentive and streamlined regulatory pathway provide a structural cost advantage.

The business model is professional services-based, with revenue generated through service contracts with biotech and pharmaceutical sponsors conducting clinical trials; no public pricing tiers or rate cards are disclosed, with commercial engagement occurring via direct consultation and custom agreements. Go-to-market is sales-led through enterprise field sales teams, 'Talk To An Expert' consultation CTAs, and content-led inbound generated by an extensive thought leadership library (white papers, disease reports, webinars, podcasts, case studies). Operational scale described in the source includes 4,450+ clinical trials, 7,260+ trial sites, 4,950+ investigators, presence in 50+ countries, and 60+ drugs advanced to market, though this scale appears materially inconsistent with the firmographic headcount range of 11-50 employees. Recent strategic momentum includes a January 2026 CEO appointment (Anand Tharmaratnam) announced from Singapore, a 2025 strategic partnership with START for oncology trials, a December 2025 early-phase oncology white paper, and support for an August 2025 Anlotinib combination therapy approval in advanced soft tissue sarcoma.

Name

Clinical Network Services (CNS)

Legal name

Novotech

Website

https://clinical.net.au

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Full-service Australian-headquartered clinical research organization (CRO) serving global biotechnology companies with integrated clinical trial services across all phases, including early-phase oncology, regulatory consulting, biometrics, real-world data analytics, and dedicated site management capabilities.

Ownership category

akta.pro rank

Headquarters

HQ city

Toowong

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Full-service CRO offering comprehensive clinical trial services including project management, site management, biometrics, regulatory affairs, and laboratory services. Revenue generated through service contracts with biotech and pharmaceutical sponsors conducting clinical trials across various phases.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Clinical Network Services (CNS) Pty Ltd is a trusted, full-service Australian clinical research organization (CRO) providing integrated biotech clinical trial services. The company delivers medical and regulatory consulting, patient recruitment, site management, biometrics, real-world data analytics, bioanalytical laboratory services, and pharmacometric services to biotechnology and pharmaceutical sponsors across all phases of drug development.

Product overview

Novotech CRO is a globally recognized full-service clinical research organization (CRO) providing comprehensive biotech partnership services across all phases of drug development. The company offers an integrated platform of services including medical and regulatory consulting, patient recruitment and site selection, early phase trials in Australia, clinical operations and project management, biometrics and data management, real world data solutions, laboratory services, and site management organization (Acrostar SMO). The portfolio also includes specialized expertise areas such as oncology, pharmacometrics, drug development consulting, GMO solutions, liver disease, infectious diseases and vaccines, orphan and rare diseases, and clinical and regulatory strategy. The FLEX service provides cost predictability and flexible scaling for ongoing clinical pipelines. Novotech operates across 50+ countries with 4450+ trials, 7260+ trial sites, 4950+ investigators, and has contributed to 60+ drugs reaching market.

Differentiator

Problem solved

Functional benefit

Brands

• Acrostar: Site Management Organization (SMO) Division operating as part of Novotech, providing clinical site management services.

Products and services

• Medical and Regulatory Consulting Full range of pre-clinical, regulatory affairs support, medical and pharmacovigilance consulting services for biotechnology and pharmaceutical sponsors.
• Patient Recruitment and Site Selection Uses in-country knowledge and real-life big data to identify and propose the best-performing clinical trial sites for biotech and pharma sponsors.
• Early Phase Trials in Australia Conducts early phase clinical trials in Australia, leveraging the country's simple and fast regulatory stream and lucrative R&D cash rebates for sponsors.
• Clinical Operations and Project Management Streamlined and integrated clinical trial services delivered by dedicated teams with deep industry and therapeutic expertise.
• Site Management Organization (SMO) - Acrostar Dedicated site management organization providing clinical excellence through specialized trial site management across the investigator network.
• Biometrics CRO and Data Management Delivers accurate, high-quality and timely biostatistics in clinical trials services, including statistical planning, analysis, regulatory submission and reporting.
• Real World Data Accelerates patient recruitment and drug development through real world data (RWD) analytics applied to clinical trial design and execution.
• Laboratory Services Bioanalytical services assisting customers in every stage of their molecule development, from preclinical through clinical phases.
• FLEX (PPC-Flex) Provides cost predictability and flexible scaling solutions for ongoing clinical pipelines, offering predictable budget plans with the ability to quickly scale up or down to meet changing needs.
• Pharmacometric Services Provides clinical study phase assistance including first-in-human, single ascending dose, and various study designs through pharmacometric analysis.
• GMO Solutions Provides genetically modified organism (GMO) clinical trial capabilities through Australia's first national, privately owned, commercial Institutional Biosafety Committee (IBC).
• Drug Development Consulting Full-service global product development and strategic regulatory group providing comprehensive lab-to-launch program support for biotechnology companies.

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• START (Cancer Therapy Research)coreStrategic or Co-development Partner · 1 January 2025Strategic partnership with START (Cancer Therapy Research) for advancing oncology trials. Featured in podcast collaboration 'Advancing Oncology Trials Together: START & Novotech' highlighting co-development in cancer therapy research.
• AcrostarcoreTechnology or IntegrationAcrostar's SMO Division operates as a dedicated entity within Novotech, providing site management organization capabilities for clinical trial site excellence.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novotech CRO: Australian-headquartered full-service biotech CRO with overlapping early-phase, oncology, regulatory, biometrics, SMO (Acrostar), and real-world data capabilities. Operates in the same Australian clinical trials ecosystem and targets the same Asia-Pacific biotech sponsor base as CNS.
• Medpace: Mid-sized, therapeutically focused full-service CRO with strong biotech customer mix. Comparable business model: full-service, science-led engagement targeting small-to-mid biotech sponsors across multiple therapeutic areas.
• Charles River Laboratories: Global CRO with a strong early-phase / discovery-to-clinical focus, including safety assessment and bioanalytical lab services. Comparable on early-phase trial execution and laboratory services components of CNS' offering.
• Worldwide Clinical Trials: Mid-sized, science-focused full-service CRO with strong therapeutic expertise (including oncology and rare disease) and a biotech-heavy customer mix similar to CNS' positioning.

Broad incumbents

• ICON plc: One of the largest global CROs after its PRA Health Sciences combination. Provides full-service clinical research across all phases and therapeutic areas, and competes with CNS for biotech-sponsored trials, especially Phase II/III.
• IQVIA: Largest global CRO and life sciences services firm, offering clinical operations, data, technology, and consulting. Competes for the same biotech and pharma sponsors that CNS targets, though at very different scale.
• Parexel International: Large full-service CRO with strong biotech and biopharma sponsor coverage. Comparable in delivering clinical operations, biometrics, regulatory, and consulting services across trial phases.
• Syneos Health: Large full-service clinical and commercial services provider serving biotech and pharma sponsors globally. Overlaps CNS' full-service clinical offering, primarily in Phase II–III programs.
• Labcorp Drug Development (formerly Covance): Large CRO with deep bioanalytical and central laboratory services integrated with clinical operations. Overlaps CNS' bioanalytical laboratory component and competes for biotech full-service mandates at much greater scale.

Regional players

• Tigermed: Leading China-based full-service CRO serving biotech and pharma sponsors across Asia-Pacific. Comparable services portfolio; competes for Asia-Pacific biotech sponsors but is anchored geographically in China rather than Australia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubevimeo.com/novotechcro
• Facebookfacebook.com/NovotechCRO
• LinkedInlinkedin.com/company/clinical-network-services

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinical Network Services (CNS)